US stock futures dip as Nvidia earnings spark little cheer
SOUTH SAN FRANCISCO - Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company with a market capitalization of $367 million, announced key executive appointments today as it prepares for late-stage development and commercialization of its drug pipeline. Jack Danilkowicz joins as Chief Commercial Officer, and Sara Klein has been promoted to Chief Legal Officer.
Danilkowicz, with a history of leading commercial strategies at Amgen (NASDAQ:AMGN) and Horizon Therapeutics (NASDAQ:HZNP), will oversee Alumis's global commercial strategy and operations, particularly for the TYK2 inhibitor pipeline. Klein, who joined Alumis in early 2022, will continue to manage all legal and compliance matters. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $25 to $38, despite the stock trading near its 52-week low.
The company is advancing its lead candidate, ESK-001, through a Phase 3 clinical program for moderate-to-severe plaque psoriasis and a potential Phase 2b trial in systemic lupus erythematosus. Additionally, Alumis is developing A-005, a CNS-penetrant TYK2 inhibitor, targeting neuroinflammatory and neurodegenerative diseases. The company maintains a strong liquidity position with a current ratio of 11.26, though InvestingPro analysis reveals 12 additional key insights about the company's financial health and market performance.
President and CEO Martin Babler expressed confidence in the new appointments, highlighting Danilkowicz's track record in launching medicines and driving market growth, and Klein's extensive experience in advising on corporate legal matters.
Alumis aims to improve the lives of patients with immune-mediated diseases through a precision approach to drug development. The company's pipeline is a result of its proprietary precision data analytics platform and drug discovery expertise.
The information in this article is based on a press release statement from Alumis Inc.
In other recent news, Alumis Inc. has made significant strides in its clinical trials and received varied analyst coverage. H.C. Wainwright reaffirmed a Buy rating on Alumis, focusing on the impact of Bristol-Myers Squibb (NYSE:BMY)'s positive Phase 3 data for its TYK2 inhibitor, Sotyktu, on Alumis's prospects. Despite Sotyktu's progress, H.C. Wainwright analysts believe that Alumis's ESK-001 has a superior profile with the potential to surpass the market share of current TYK2 inhibitors.
Alumis also announced the successful completion of a Phase 1 clinical trial for its drug candidate A-005, a TYK2 inhibitor intended to treat multiple sclerosis (MS). The trial involved 135 healthy participants and demonstrated that A-005 was well tolerated, with no serious adverse events reported.
Furthermore, Alumis has updated the estimated primary and study completion dates for its Phase 2 LUMUS clinical trial, evaluating the efficacy, safety, and pharmacokinetics of the investigational drug ESK-001 in adult patients with systemic lupus erythematosus (SLE).
In terms of analyst coverage, Baird initiated coverage on Alumis with an Outperform rating and a price target of $25.00. Despite a price target adjustment from H.C. Wainwright, reducing its target to $26 from $30, the firm maintained its Buy rating on Alumis. These recent developments underscore Alumis's ongoing efforts in the biopharmaceutical space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.